What is Pleno?
Pleno Inc. operates as a multi-omic instrument platform company dedicated to the democratization of biological target detection. At the core of its value proposition is the proprietary Hypercoding technology, which applies sophisticated signal processing methodologies to biological data. This approach allows for the delivery of targeted information at an unprecedented scale, precision, and performance level. By bridging the gap between complex telecommunications signal processing and life sciences, Pleno provides researchers and clinicians with the tools necessary to unlock deeper insights into biological systems, thereby enhancing the efficacy of diagnostic workflows and accelerating the pace of biomedical discovery.
How much funding has Pleno raised?
Pleno has raised a total of $80M across 3 funding rounds:
Other Financing Round
$15M
Series A
$40M
Series B
$25M
Other Financing Round (2022): $15M with participation from Medical Excellence Capital and Alexandria Venture Investments
Series A (2022): $40M led by Foresite Capital and Deerfield
Series B (2024): $25M supported by Foresite Capital, Medical Excellence Capital, and Deerfield Management Group
Key Investors in Pleno
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
Medical Excellence Capital
Medical Excellence Capital is an early-stage life sciences venture fund focused on advancing precision health innovations through precision capital and a proprietary national medical network.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem.
What's next for Pleno?
With the successful closure of this major strategic investment, Pleno is well-positioned to expand its commercial footprint and refine its multi-omic instrument suite. The company is expected to prioritize the scaling of its Hypercoding platform to meet the growing demand for high-throughput biological analysis in clinical settings. Strategic focus will likely shift toward deepening partnerships with healthcare providers and research institutions, ensuring that their technology becomes a standard component of modern diagnostic infrastructure. As the company matures, the integration of its data-rich outputs into broader precision health ecosystems will be a key performance indicator for its long-term market leadership and technological dominance in the life sciences sector.
See full Pleno company page
